Investors benefit from our depth of coverage in the healthcare landscapeContact Us
Our perspective is driven by significant Wall Street and investment analysis experience, combined with the industry and management consulting backgrounds that many of our research professionals possess. In addition, we derive critical insights from MEDACorp – a network of 20,000+ key opinion leaders and industry practitioners.
We cover companies spanning Biotechnology; Digital Health; Healthcare Services; Lifescience Tools and Diagnostics; and Medical Supplies and Devices.
Biopharma / Immuno-Oncology / Debates & Questions After the Positive OS Trend with Roche’s TIGIT in SKY-01
Biopharma / Diversified Biopharmaceuticals / JNJ — Flash / Oral IL-23 BID Efficacy Similar to Stelara but Below Injectable IL-23s / Outperform
Biopharma / ASCO Single-Agent Responses with IO, but Context Matters for BOLT, IPHA, AFMD
Andrew Berens, M.D.
Senior Managing Director, Targeted Oncology
Andrew Berens, M.D., is a Senior Research Analyst at Leerink Partners covering Targeted Oncology.
Prior to joining the firm in 2018, Andrew was an Executive Director and Senior Biotechnology Research Analyst at Morgan Stanley focusing on mid- and small-cap biotechnology companies. He practiced as an emergency medicine physician for a decade before starting his career in equity research. He also worked in the pharma industry at Ikaria Pharmaceuticals, where he was a Senior Director in business development, leading search and development efforts.
In 2017 he was named a Runner Up in Institutional Investor’s 2017 All–America Research Team for Biotechnology/Mid- & Small-Cap.
He earned M.B.A. degrees from Columbia Business School and London Business School, his M.D. from Emory University, and an undergraduate degree in English Literature from Tulane University.
Jonathan Chang, Ph.D., CFA
Senior Managing Director, Emerging Oncology
Jonathan Chang, Ph.D., CFA is a Senior Research Analyst at Leerink Partners covering Emerging Oncology. He has been an important contributor to the firm’s biotechnology research product and insights.
Jonathan joined the firm in 2013 as an Associate supporting the firm’s senior oncology biotechnology research team and in 2016, he assumed research coverage of several important emerging biotechnology companies. In 2018, he was named a Rising Star in Institutional Investor’s 2018 All-America Research Team for Biotechnology/Mid- & Small-Cap.
He earned a Ph.D. in Pharmacology from Cornell University, an M.A. in Biotechnology from Columbia University, and an Honors B.Sc. in Genes, Genetics, and Biotechnology from the University of Toronto. Dr. Chang is a CFA charter holder.
Senior Managing Director, Healthcare Technology and Distribution
Stephanie Davis, CFA, is a Senior Research Analyst at Leerink Partners covering Healthcare Technology and Distribution. She has over a decade of experience covering the Healthcare IT and IT Services sectors and leads the firm’s digital health research efforts.
Prior to joining the firm, Stephanie worked at Citibank, where she led coverage for the Healthcare IT sector, including the electronic health record companies, payer-facing and provider-facing IT players. Before Citi, she was an Equity Research Analyst at J.P. Morgan and, earlier in her career, was an Investment Banking Analyst at Sonenshine Partners.
In 2019, Stephanie was recognized as a Runner-Up for Health Care Technology and Distribution on Institutional Investor’s All America Research Team and was included in Business Insider’s “Rising Stars of Equity Research” in 2017.
She earned a B.A. in Economics and Mathematics from Columbia University and is a CFA charter holder.
Mani Foroohar, M.D.
Senior Managing Director, Genetic Medicines
Mani Foroohar, M.D., is a Senior Research Analyst within our Therapeutics team focusing on Genetic Medicines.
Mani joined Leerink Partners from Aptigon Capital, a Citadel Company, where he most recently was a Therapeutics Analyst focused on U.S. and EU biotechnology, major pharmaceuticals and specialty pharmaceuticals sectors. Prior to Aptigon, he was an Analyst at Green Owl Capital Management and an Assistant Vice President of Equity Research at Barclays. In 2013, Mani co-founded Cellanyx Diagnostics, a company developing a proprietary live tumor cell, phenotypic platform for precision risk stratification in cancer to inform clinical treatment decision-making.
He holds an M.D. from Stanford, where he was a Howard Hughes Medical Institute Research Fellow in the Department of Genetics, an M.B.A. from Columbia, and a B.S. from UCLA.
Senior Managing Director, Neuroscience
Marc Goodman is a Senior Research Analyst at Leerink Partners covering Neuroscience and Ophthalmology.
Prior to joining the firm in 2018, Marc was most recently a Managing Director and U.S. Healthcare Analyst at UBS Investment Bank, where he focused on large-cap and specialty pharmaceuticals sectors. Prior to UBS, he covered specialty pharmaceuticals and generics sectors for over 15 years as a Managing Director at Crédit Suisse AG and as an Executive Director at Morgan Stanley.
Marc has been ranked by Institutional Investor as a top analyst in Specialty Pharmaceuticals for well over a decade and has also expanded his coverage and interests into global and emerging biopharmaceutical companies in recent years.
He earned his MBA from The Ohio State University and his B.A. in Economics from Tufts University.
Daina Graybosch, Ph.D.
Senior Managing Director, Immuno-Oncology
Daina Graybosch, Ph.D., is a Senior Research Analyst at Leerink Partners covering Immuno-Oncology.
Prior to joining the firm in 2018, Daina worked at McKinsey & Company as a Senior Expert and Head of McKinsey’s Center for Asset Optimization, as well as the U.S. Head of the McKinsey Cancer Center. In these roles, she developed several McKinsey solutions that bring data and advanced analytics to pharmaceutical development decisions. In her 11 years at McKinsey, she developed a rich understanding of oncology through her work with companies across the value chain, including Pharmaceutical, Diagnostic, Academic Medical Center, and Genomic/Data.
She earned a Ph.D. in Chemistry and Chemical Biology from Harvard University and dual B.S. degrees in Biology and Chemistry from the University of Utah.
Senior Managing Director, Healthcare Providers & Managed Care
Whit Mayo is a Senior Managing Director and Senior Research Analyst covering Healthcare Providers & Managed Care at Leerink Partners. He leads Leerink Partners’ research across payors, providers, and health systems and provides strategic guidance and insight for our clients and partners.
Whit joined the firm in 2021 from UBS, where he most recently served as Managing Director. Prior to that, Whit covered the sector at Baird and Stephens, Inc.
In 2020 he was ranked in Institutional Investor’s All-America Research Team within the Health Care Facilities & Managed Care category.
He earned his Bachelor of Arts in Economics at Sewanee, The University of the South.
David Risinger, CFA
Senior Managing Director, Biopharma
David Risinger, CFA is a Senior Managing Director and Senior Research Analyst at Leerink Partners covering Diversified Biopharmaceuticals.
Prior to joining the firm in 2022, David’s most recent Wall Street role was Head of US Major and Specialty Pharmaceuticals Equity Research for Morgan Stanley & Co. Prior to Morgan Stanley, he was head of Global Healthcare Research and Senior US Pharmaceutical analyst at Merrill Lynch & Co. He started his Wall Street career at Dillon, Read & Co. He has been a top-ranked analyst by Institutional Investor for decades, including achieving Runner-Up rankings in both Major Pharmaceuticals and Specialty Pharmaceuticals in 2021.
He earned his Bachelor of Arts in Political Science from Bucknell University and holds the Chartered Financial Analyst designation.
Roanna Ruiz, Ph.D.
Senior Managing Director, Infectious Disease, Endocrine & Cardiovascular Disorders
Roanna Ruiz, Ph.D., is a Senior Research Analyst at Leerink Partners covering Infectious Disease, Endocrine and Cardiovascular Disorders (IDECV). She excels in quality of research, depth of insights and understanding, and the service provided to the firm’s internal and external clients. Prior to covering the IDECV sectors, she was a core member of Leerink Partners’ Neuroscience team helping to deliver science-forward and deep-dive fundamental research to clients.
Roanna joined the firm in 2018 after holding equity research roles at UBS and H.C. Wainwright. Previously, Roanna spent two years in pharmaceutical industry consulting at IQVIA working on M&A, product launch strategy, and pricing & reimbursement projects.
She earned a Ph.D. in Biomedical Engineering from Cornell University, and a B.S. in Engineering Sciences from Harvard University.
Joseph P. Schwartz
Senior Managing Director, Rare Diseases
Joseph Schwartz is a Senior Research Analyst at Leerink Partners covering Rare Diseases.
Prior to joining the firm in 2003, Joseph provided economic and strategic consulting services to biotechnology and pharmaceutical companies with Charles River Associates. Earlier in his career, he held equity research positions at SG Cowen, State Street Research, and J.P. Morgan, where he analyzed the fundamental performance drivers of investments in the health care, retail, consumer, media, and entertainment sectors.
He was named #1 Stock Picker for Pharmaceuticals in the 2011 FT/StarMine Analyst Awards. In 2010, he earned the Wall Street Journal’s #1 ranking for biotech stock picking as part of its “Best on the Street” analysts survey, which topped his #2 ranking in the Journal’s 2008 “Best on the Street” rankings.
He earned an M.B.A. from Babson College and a B.A. in Economics from Colby College.
Thomas J. Smith
Senior Managing Director, Immunology and Metabolism
Thomas J. Smith is a Senior Research Analyst at Leerink Partners covering Immunology and Metabolism. Prior to covering the Immunology and Metabolism sector, Thomas was a key member of Leerink Partners’ Targeted Oncology team helping to deliver in-depth fundamental research to clients.
Prior to joining the firm in 2018, Thomas was most recently a Vice President and Research Analyst at Morgan Stanley, covering leading and emerging biopharmaceutical companies across numerous therapeutic areas, including oncology, NASH, and lead coverage of women’s health companies. Prior to that, he worked at FBR Capital Markets on the biotechnology team, responsible for coverage of large, mid- and small-cap companies. Thomas began his career at Bloomberg, where he held roles of increasing responsibility, including coverage of the biotech and specialty pharmaceutical sectors for Bloomberg Intelligence.
He earned his B.S. in Finance and Psychology from The College of New Jersey.
Senior Managing Director, Life Science Tools and Diagnostics
Puneet Souda is a Senior Research Analyst at Leerink Partners covering Life Science Tools and Diagnostics. His research focuses on companies and technologies within the Life Science Tools subsector, the Diagnostics subsector, and selected areas of Pharmaceutical Services.
Prior to joining the firm in 2014, Puneet was a Senior Associate at Citigroup covering Medical Devices. Before joining Wall Street, he spent over a decade in core and basic research labs at UCLA and Purdue University. In this work, he was a customer and collaborator of many Life Science Tools and Diagnostic companies. Puneet has direct experience in the acquisition, management, and utilization of many life sciences technologies for molecular analysis and diagnostics. He has co-authored over 45 peer-reviewed scientific papers and has built an extensive network of colleagues and collaborators among academic lab researchers and Life Science Tools suppliers.
He earned an M.B.A. from University of California-San Diego and undertook graduate study in biotechnology and earned a B.A. in Biology from Purdue University.
Senior Managing Director, Director of Research
Jim Kelly is a Senior Managing Director, Director of Research at Leerink Partners. Mr. Kelly is responsible for product management, analyst development and equity strategy.
Prior to joining Leerink Partners in 2015, Mr. Kelly worked at Credit Suisse, where he served in research management as an Associate Director of Equity Research in New York and was responsible for leading key, strategic initiatives in research product and process development. Prior to his ADOR role at Credit Suisse, Mr. Kelly spent 13 years in Equity Research covering the US Pharmaceuticals industry for Lehman Brothers, Goldman Sachs and Credit Suisse First Boston.
Mr. Kelly received his M.B.A. from Columbia Business School and earned his B.S. in Mechanical Engineering from Lehigh University. Mr. Kelly also serves on the board of the Lehigh Business School Dean’s Advisory Council.
Managing Director, Associate Director of Research
Julia Belladonna is a Managing Director, Associate Director of Research at Leerink Partners.
Julia joined the firm in 2021 from Credit Suisse where she spent 20+ years in a variety of roles, most recently as the COO of Global Economics for their Institutional client & Private Wealth Management businesses. She brings over two decades of experience in financial markets, business and talent management, international regulatory requirements, and operations. She has excelled in managing complex groups, collaborating across business units, and developing strategies to deliver research to clients. Prior to Credit Suisse, she was an Industry Analyst at Merrill Lynch.
Julia earned a B.A. in Applied Mathematics and History from Williams College and an M.B.A. in Finance from Columbia Business School.